Olprinone Hydrochloride, also known as Loprinone, is a phosphodiesterase (PDE) 3 potent inhibitor, exhibiting IC50 values of 150, 100, 0.35, and 14 μM for PDE1, PDE2, PDE3, and PDE4, respectively. It is utilized in heart failure research for its positive inotropic and vasodilative properties. It also exhibits anti-inflammatory activity [1] [2].

Olprinone (Loprinone) Hydrochloride (0.2 mg/kg; i.p.) effectively mitigates inflammation and reduces myocardial damage in ischemia-reperfusion injury within male adult Wistar rats (250-300 g) designated as ischemia–reperfusion models. Administered intraperitoneally 15 minutes post-ischemia, it markedly lowers histologic signs of cardiac injury, diminishes levels of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and Interleukin-1β (IL-1β), decreases expression of adhesion molecules such as Inter-Cellular Adhesion Molecule 1 (ICAM-1) and P-Selectin, reduces nitrotyrosine formation, suppresses nuclear factor kappa-B (NF-κB) expression, curtails Poly (ADP-ribose) (PAR) formation, and lessens apoptosis, as evidenced by alterations in Bax, Bcl-2, Fas-L levels and terminal deoxynucleotidyl transferase-mediated UTP end labeling (TUNEL) outcomes.